Cardiovasc Diabetol July 2023 PMID 37407956

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial.

Martin Benedikt, Harald Mangge, Faisal Aziz, Pero Curcic, Sabine Pailer, Markus Herrmann, Ewald Kolesnik, Norbert J Tripolt, Peter N Pferschy, Markus Wallner, Andreas Zirlik, Harald Sourij, Dirk von Lewinski

Full text PDF Download social card

Mentions

Peak: 3 in Jul 2023

across 2 sources since Jul 2023

Extended reach

6,310

potential audience

Total likes

Video views

Mentions per month

Jul 2023 – Oct 2023

Where it's discussed

X / Twitter3 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions demonstrate genuine interest and moderate engagement, with users highlighting elements like the inflammatory biomarkers (IL-6, hsCRP) and the potential role of Empagliflozin in post-MI care, using words like 'significant' and 'may help' to convey cautious optimism. The tone varies from analytical to hopeful, reflecting a balanced perception of the research's importance.

AgreementModerate agreement

Most discussions reflect a positive view of the study's implications, with some users emphasizing the potential benefits of Empagliflozin in reducing inflammation after a heart attack.

InterestHigh interest

The posts show high curiosity about the research, referencing specific biomarkers and questioning the effects, indicating substantial interest.

EngagementModerate engagement

Some users delve into detailed analysis of the study's results and their clinical significance, but several simply acknowledge the findings without deep discussion.

ImpactModerate impact

There is a recognition of the study's potential influence on future treatments, though comments stop short of calling it a game-changer.

Abstract in brief

The EMMY trial demonstrated that Empagliflozin, an SGLT2-inhibitor, significantly reduced NTproBNP levels and improved cardiac structure in post-acute myocardial infarction (AMI) patients compared to placebo.
A post-hoc analysis involving 374 patients examined changes in inflammatory biomarkers after 26 weeks, revealing significant reductions in IL-6, hsCRP, neutrophils, leukocytes, and neutrophil/lymphocyte ratio (NLR), with no notable differences between the Empagliflozin and placebo groups.
The findings suggest SGLT2-inhibitors like Empagliflozin may help mitigate inflammation after AMI, although further research is needed

Read the full abstract

All mentions

Empagliflozin's Effect on Inflammatory Biomarkers Post-Myocardial Infarction

The EMMY trial shows Empagliflozin significantly reduced inflammatory biomarkers like IL-6 and hsCRP after acute myocardial infarction. A post-hoc analysis of 374 patients highlights its potential role in mitigating…

Social RTCL TV · Oct 17, 2023 35 views

part time scientist

@Sevil3571739841 · X

RT @Miguel_A_Maria: Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc a…

Jul 11, 2023 · 1 share · 4 followers View post →

Miguel A. Maria. Medico de Familia

@Miguel_A_Maria · X

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial https://t.co/U7L5bVmXWL https://t.co/V8Yz6x4NZt

Jul 11, 2023 · 3 likes · 1 share · 1,366 followers View post →

宇津貴史 /Utsu, Takashi

@Office_j · X

Jul 6, 2023 · 2 likes · 4,902 followers View post →